RT Journal Article
SR Electronic
T1 Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6977
OP 6981
VO 37
IS 12
A1 SENTO, SHINYA
A1 KITAMURA, NAOYA
A1 YAMAMOTO, TETSUYA
A1 NAKASHIRO, KOICHI
A1 HAMAKAWA, HIROYUKI
A1 IBARAGI, SOICHIRO
A1 SASAKI, AKIRA
A1 TAKAMARU, NATSUMI
A1 MIYAMOTO, YOJI
A1 KODANI, ISAMU
A1 RYOKE, KAZUO
A1 MISHIMA, KATSUAKI
A1 UEYAMA, YOSHIYA
A1 ORAL CANCER STUDY GROUP OF CHUGOKU-SHIKOKU
YR 2017
UL http://ar.iiarjournals.org/content/37/12/6977.abstract
AB Background/Aim: To evaluate the efficacy of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) in oral cancer patients. Patients and Methods: Oral cancer patients receiving HEC were enrolled; among the 40 patients, 87 courses of chemotherapy were administered. On day 1, 0.75 mg palonosetron was intravenously administrated just before chemotherapy. Results: The primary endpoint was the proportion of patients with a complete response (CR) and the secondary endpoint was the proportion of patients with complete control (CC) during the acute and delayed phase. During the acute phase, 86 of 87 courses (98.9%) had CR and 84 of 87 courses (96.6%) had CC. During the delayed phase, 84 of 87 courses (96.6%) had CR and 70 of 87 courses (80.5%) had CC. Conclusion: Palonosetron is effective at preventing HEC-induced chemotherapy-induced nausea and vomiting (CINV) in oral cancer chemotherapeutic regimens in the acute and delayed phases.